Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia 53Lymphoma 51Melanoma 44Breast Neoplasms 37Lymphoma, Follicular 36Leukemia, Myeloid, Acute 33Leukemia, Lymphocytic, Chronic, B-Cell 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Lymphoma, Non-Hodgkin 29Neuroblastoma 28Multiple Myeloma 28Lymphoma, Large B-Cell, Diffuse 25Prostatic Neoplasms 24Lymphoma, Mantle-Cell 23Myelodysplastic Syndromes 22Lymphoma, Large-Cell, Immunoblastic 20Neoplasms, Plasma Cell 19Leukemia, Myeloid, Chronic-Phase 19Lung Neoplasms 18Hodgkin Disease 18Carcinoma, Non-Small-Cell Lung 18Burkitt Lymphoma 18Ovarian Neoplasms 17Lymphoma, B-Cell, Marginal Zone 17Neoplasm Metastasis 16Glioblastoma 16Leukemia, Myelogenous, Chronic, BCR-ABL Positive 15Congenital Abnormalities 15Leukemia, Myeloid, Accelerated Phase 14Colorectal Neoplasms 13

Interventions

pembrolizumab 14Injections 13Paclitaxel 10Nivolumab 10Docetaxel 9Cisplatin 9Capecitabine 9Bevacizumab 8toripalimab 7senaparib 7Fluorodeoxyglucose F18 7Cyclophosphamide 7tislelizumab 6atezolizumab 6Irinotecan 6Fluorouracil 6Gemcitabine 5fludarabine 4apatinib 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Carboplatin 4spartalizumab 3sintilimab 3pertuzumab 3olaparib 3camrelizumab 3Rifampin 3Radiosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumor × sargramostim × Clear all
NCT05284214 2023-09-15

SALIENT

Partner Therapeutics, Inc.

Phase 2 Withdrawn
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡